Structural changes in Parkinson’s disease: voxel-based morphometry and diffusion tensor imaging analyses based on 123I-MIBG uptake

European Radiology

Volumn 27, Issue 12, 2017, Pages 5073-5079

  Kikuchi, Kazufumi ^a   Hiwatashi, Akio ^a   Togao, Osamu ^a   Yamashita, Koji ^a   Somehara, Ryo ^a   Kamei, Ryotaro ^a   Baba, Shingo ^a   Yamaguchi, Hiroo ^a   Kira, Jun ichi ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Diffusion tensor imaging; Magnetic resonance imaging; Neurodegenerative diseases; Parkinson s disease; Radionuclide imaging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BRAIN SCINTISCANNING; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIFFUSION TENSOR IMAGING; FEMALE; FRACTIONAL ANISOTROPY; GRAY MATTER; HEART; HOEHN AND YAHR SCALE; HUMAN; INFERIOR FRONTAL GYRUS; MALE; MEDIASTINUM; MINI MENTAL STATE EXAMINATION; NEUROANATOMY; NEUROIMAGING; OCCIPITOFRONTAL FASCICULUS; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUPERIOR LONGITUDINAL FASCICULUS; SYMPATHETIC TONE; THALAMUS ANTERIOR NUCLEUS; UNCINATE FASCICULUS; VOXEL BASED MORPHOMETRY; WHITE MATTER; ADULT; ANISOTROPY; BRAIN; EVALUATION STUDY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; SCINTISCANNING; VERY ELDERLY;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; ANISOTROPY; BRAIN; DIFFUSION TENSOR IMAGING; FEMALE; GRAY MATTER; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; WHITE MATTER;

EID: 85021804558     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-017-4941-6     Document Type: Article

References (40)

1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525–535
2. Obeso JA, Rodriguez-Oroz MC, Rodriguez M et al (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23:S8–S19
3. Hattori T, Orimo S, Hallett M et al (2014) Relationship and factor structure in multisystem neurodegeneration in Parkinson's disease. Acta Neurol Scand 130:347–353
4. Sisson JC, Shapiro B, Meyers L et al (1987) Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625–1636
5. Mantysaari M, Kuikka J, Mustonen J et al (1992) Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine. Diabetes 41:1069–1075
6. Yoshita M (1998) Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67
7. Hakusui S, Yasuda T, Yanagi T et al (1994) A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81–84
8. Orimo S, Takahashi A, Uchihara T et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17:24–30
9. Orimo S, Kanazawa T, Nakamura A et al (2007) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113:81–86
10. Gattellaro G, Minati L, Grisoli M et al (2009) White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 30:1222–1226
11. Schrag A, Good CD, Miszkiel K et al (2000) Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 54:697–702
12. Vymazal J, Righini A, Brooks RA et al (1999) T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211:489–495
13. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT (2004) Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127:791–800
14. Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB (2012) White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage 62:1675–1684
15. Karagulle Kendi AT, Lehericy S, Luciana M, Ugurbil K, Tuite P (2008) Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 29:501–505
16. Zhang K, Yu C, Zhang Y et al (2011) Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. Eur J Radiol 77:269–273
17. Salsone M, Cerasa A, Arabia G et al (2014) Reduced thalamic volume in Parkinson disease with REM sleep behavior disorder: volumetric study. Parkinsonism Relat Disord 20:1004–1008
18. Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30:1591–1601
19. Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treat 5:257–282
20. Yonezawa M, Nagao M, Abe K et al (2013) Relationship between impaired cardiac sympathetic activity and spatial dyssynchrony in patients with non-ischemic heart failure: assessment by MIBG scintigraphy and tagged MRI. J Nucl Cardiol 20:600–608
21. Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38:95–113
22. Smith SM, Jenkinson M, Johansen-Berg H et al (2006) Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 31:1487–1505
23. Smith SM, Jenkinson M, Woolrich MW et al (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23:S208–S219
24. Mori S, Oishi K, Jiang H et al (2008) Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage 40:570–582
25. Smith SM, Nichols TE (2009) Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 44:83–98
26. Palma JA, Kaufmann H (2014) Autonomic disorders predicting Parkinson's disease. Parkinsonism Relat Disord 20:S94–S98
27. Cubo E, Martin PM, Martin-Gonzalez JA, Rodriguez-Blazquez C, Kulisevsky J, Members EG (2010) Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. Mov Disord 25:70–75
28. Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T (2014) MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord 20:267–273
29. Cacciola A, Milardi D, Anastasi GP et al (2016) A Direct Cortico-Nigral Pathway as Revealed by Constrained Spherical Deconvolution Tractography in Humans. Front Hum Neurosci 10:374
30. Sesack SR, Deutch AY, Roth RH, Bunney BS (1989) Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 290:213–242
31. Kunzle H (1978) An autoradiographic analysis of the efferent connections from premotor and adjacent prefrontal regions (areas 6 and 9) in macaca fascicularis. Brain Behav Evol 15:185–234
32. Kwon HG, Jang SH (2014) Differences in neural connectivity between the substantia nigra and ventral tegmental area in the human brain. Front Hum Neurosci 8:41
33. Peran P, Cherubini A, Assogna F et al (2010) Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133:3423–3433
34. Hattori T, Orimo S, Aoki S et al (2012) Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 33:727–739
35. Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH (2011) The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 26:289–296
36. Nishio Y, Hirayama K, Takeda A et al (2010) Corticolimbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol 17:1090–1097
37. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249:III/1–III/5
38. Chan LL, Rumpel H, Yap K et al (2007) Case control study of diffusion tensor imaging in Parkinson's disease. J Neurol Neurosurg Psychiatry 78:1383–1386
39. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300
40. Woo CW, Krishnan A, Wager D (2014) Cluster-extent based thresholding in fMRI analyses: Pitfalls and recommendations. Neuroimage 91:412–419